Twist Bioscience is making strategic moves to enhance its investment narrative through a new financing program aimed at bolstering its role in AI-driven genomics.
In June 2026, Twist Bioscience initiated an extensive shelf registration that includes a $200 million at-the-market equity offering. This move not only provides the company with increased financial flexibility but also positions it prominently in the liquid biopsy and AI genomics sectors. The interest from Osterweis Opportunity Fund further emphasizes Twist's potential as an outsourced lab for AI applications in genomics, suggesting a robust intersection of synthetic DNA and artificial intelligence.
The company's investment narrative hinges on the belief that its synthetic DNA platform can become vital for next-generation sequencing and synthetic biology. However, ongoing losses and substantial research expenditures raise concerns about future equity dilution. While the recent funding initiatives may alleviate some immediate financial pressures, investors must remain cautious about the possibility of further equity issuance if losses persist.
Analysts project that Twist could achieve $660.4 million in revenue by 2029, although some forecasts indicate a more pessimistic outlook with no profits anticipated. As investors evaluate Twist's new financing capabilities alongside its AI genomics exposure, it is crucial to weigh these varied perspectives and form a well-informed view on the company's future potential.